Patent Research Patent research report on ATM inhibitors in the field of synthetic lethality

Patented Research Report Series, launched by the Biomedical Department of Smart Buds, selects new targets and new mechanisms worthy of attention, and conducts detailed research and analysis around the target, including the elaboration of the mechanism of action, the patent layout of listed drugs and drugs under development and the detailed interpretation of key patents, etc.
, presenting the target development panorama
from the perspective of patents.

This series of reports takes ATM inhibitors in the field of synthetic lethality as the research object, and conducts detailed patent research and analysis
on them.

Synthetic lethality, from the birth of theory to the landing of drugs, has brought more clinical drug options
for the treatment of advanced ovarian cancer.
The commercial success of this field, the representative drug PARP inhibitor, has grown into a large class of anti-tumor drugs with annual sales of billions of dollars, and its commercial success not only objectively confirms the correctness of the synthetic lethality theory, but also plays a positive role
in promoting the research of related targets in this field.

ATM, as a potential target of synthetic lethal theory, has been deployed by many well-known pharmaceutical companies at home and abroad, such as foreign pharmaceutical companies AstraZeneca, Merck, and Shanghai Yingpai Pharmaceutical, which focuses on the research and development of new drugs in the field of synthetic lethality, and Nanjing Mingde new drugs mass-produced by IND varieties
.
Overall, the development of ATM inhibitors has made substantial progress
, whether based on the exploration of FIC varieties or the occupancy of fastfollow varieties.

Figure: ATM-related cell cycle-DSB-signaling pathway ( Figure: Progress in the development of synthetic lethal antitumor drugs.
Biomedical Translativation, 2022, 3(01).
）

At this stage, ATM target drugs have not been approved for marketing, and there are mainly 3 ATM inhibitors that have entered the clinical stage, namely AZD-1390 of AstraZeneca, M-4076 of MerckKGaA, XRadTherapeutics XRD-0394 (structure not disclosed, and ATM/DNA-PK dual target inhibitor), the overall is in the clinical phase I stage, the indication is mainly solid tumor, covering glioblastoma, Metastatic brain cancer, squamous cell carcinoma
of the head and neck.

In addition to the above-mentioned new drug R&D companies and clinical research varieties, for the development of ATM inhibitors, there are also many pharmaceutical companies for their drug and patent layout, including foreign pharmaceutical companies such as KuDOSPharmaceuticals Ltd, domestic pharmaceutical companies such as Shanghai Yingpai Pharmaceutical, Nanjing Mingde New Drug, Suzhou Zanrong, etc
.

After detailed patent research, the report analyzes and interprets the track: